Sheet 1 of 1Substitute Form PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark OfficeAttorney's Docket No.
01948-056001Application No.
09/855,313**Information Disclosure Statement
by Applicant**

(Use several sheets if necessary)

(37 CFR §1.98(b))

Applicant

Terry B. Strom *et al.*

Filing Date

May 14, 2001

Group Art Unit

~~1645~~ 1647**U.S. Patent Documents**

Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

RECEIVED

APR 01 2002

TECH CENTER 1600/2900

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
12/05/03 FH	AL	DE 19823351 A1	10/12/98	Germany				
FH	AM	WO 9741232 A	06/11/97	WIPO				
FH	AN	WO 9626274 A	29/08/96	WIPO				
	AO							
	AP							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
FH	AQ	Agostini <i>et al.</i> , <i>Blood</i> , v93 (No. 4), pp. 1277-1286 (Feb. 1999)
FH	AR	Ferrari-Lacraz <i>et al.</i> , <i>Jrl. Of Immuno.</i> , v167 (No. 6), pp. 3478-3485 (Se. 2001)
FH	AS	Kim <i>et al.</i> , <i>Jrl. Of Immuno.</i> , v160 (No. 12), pp. 5742-5748 (Je. 1998)
FH	AT	Kim <i>et al.</i> , <i>Transplantation Proceedings</i> , v30 (No. 8), pp. 4031-4036 (1998)


Examiner Signature

Date Considered

3/6/02

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

Sheet 1 of 3Substitute Form PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark OfficeAttorney's Docket No.
01948-056001Application No.
09/855,313**Information Disclosure Statement
by Applicant**

(Use several sheets if necessary)

(37 CFR §1.98(b))

Applicant
Terry B. Strom, et al.Filing Date
May 14, 2001Group Art Unit
~~1645~~ 1647**U.S. Patent Documents**

Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
FH	AA	5,116,964	May 26, 1992	Capon, et al			
FH	AB	5,552,303	Sept. 3, 1996	Grabstein, et al			
FH	AC	5,574,138	Nov. 12, 1996	Grabstein, et al			SEP 16 2003
FH	AD	5,707,616	Jan. 13, 1998	Grabstein, et al			
FH	AE	5,747,024	May 5, 1998	Grabstein, et al			
FH	AF	5,892,001	Apr. 6, 1999	Grabstein, et al			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
FH	AG	WO 88/07089	22 Sept 1988	WIPO				
FH	AH	WO 93/08207	29 Apr 1993	WIPO				
FH	AI	WO 93/19770	14 Oct 1993	WIPO				
FH	AJ	WO 94/04180	3 Mar 1994	WIPO				
FH	AK	WO 94/04570	3 Mar 1994	WIPO				
FH	AL	WO 94/17773	18 Aug 1994	WIPO				
FH	AM	WO 95/06480	9 Mar 1995	WIPO				
FH	AN	WO 95/06481	9 Mar 1995	WIPO				
FH	AO	WO 95/06666	9 Mar 1995	WIPO				
FH	AP	WO 95/27722	19 Oct 1995	WIPO				
FH	AQ	WO 95/28957	2 Nov 1995	WIPO				
FH	AR	WO 96/16665	6 Jun 1996	WIPO				
FH	AS	WO 96/23071	1 Aug 1996	WIPO				
FH	AT	WO 96/26274	29 Aug 1996	WIPO				
FH	AU	WO 96/40246	19 Dec 1996	WIPO				
FH	AV	WO 97/17446	15 May 1997	WIPO				
FH	AW	WO 97/20063	5 Jun 1997	WIPO				
FH	AX	WO 97/22256	26 Jun 1997	WIPO				

Examiner Signature

Date Considered

12/01/03

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 01948-056001	Application No. 09/855,313
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Terry B. Strom, et al.	
		Filing Date May 14, 2001	Group Art Unit 1645 1647

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
FH	AY	WO 97/26000	24 Jul 1997	WIPO				
FH	AZ	WO 97/34633	25 Sep 1997	WIPO				
FH	AAA	WO 98/01145	15 Jan 1998	WIPO				
FH	ABB	WO 98/52606	26 Nov 1998	WIPO				
FH	ACC	WO 98/56417	17 Dec 1998	WIPO				
FH	ADD	WO 98/58672	30 Dec 1998	WIPO				
FH	AEE	WO 99/00143	7 Jan 1999	WIPO				
FH	AFF	WO 99/12566	18 Mar 1999	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
FH	AGG	Lin, et al. <i>The Role of Shared Receptor Motifs and Common Stat Proteins in the Generation of Cytokine Pleiotropy and Redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15.</i> Immunity, 2:331-339 (Apr. 1995).
FH	AHH	Morrison, et al. <i>Structural Determinants of Human IgG Function.</i> The Immunologist 2(4):119-124 (1994).
FH	AII	Brekke, et al. <i>Structure-Function Relationships of Human IgG.</i> The Immunologist 2(4):125-130 (1994).
FH	AJJ	Pettit, et al. <i>Structure-Function Studies of Interleukin 15 using Site-specific Mutagenesis, Polyethylene Glycol Conjugation, and Homology Modeling.</i> The Journal of Biological Chemistry 272(4): 2312-2318 (1997).
FH	AKK	Stevens, et al. <i>Interleukin-15 signal, T84 colonic epithelial cells in the absence of the interleukin-2 receptor β-chain.</i> Am. J. Physiol. 272:G1-G8 (1997).
FH	ALL	Armitage, et al. <i>IL-15 Has Stimulatory Activity for the Induction of B Cell Proliferation and Differentiation.</i> Journal of Immunology 154:483-490 (1995).
FH	AMM	Chae, et al. <i>Distribution of IL-15 Receptor α-Chains on Human Peripheral Blood Mononuclear Cells and Effect of Immunosuppressive Drugs on Receptor Expression.</i> Journal of Immunology 157:2813-2819 (1996).
FH	ANN	Moreland, et al. <i>Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)-Fc Fusion Protein.</i> N. Engl. J. Med 337(3):141-147 (1997).
FH	AOO	Elliott, et al. <i>Repeated therapy with monoclonal antibody to tumor necrosis factor α (cA2) in patients with rheumatoid arthritis.</i> Lancet 344(8930):1125-1127 (1994).
FH	APP	Elliott, et al. <i>Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis.</i> Lancet 344(8930):1105-1110 (1994).
FH	AQQ	Williams, et al. <i>Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4.</i> Immunology 84(3): 433-439 (1995).

Examiner Signature <i>for [Signature]</i>	Date Considered 12/01/03
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449

U.S. Department of Commerce
Patent and Trademark Office

Attorney's Docket No.

01948-056001

Application No.

09/855,313

Information Disclosure Statement
by Applicant

Use several sheets if necessary)

Applicant

Terry B. Strom, et al.

Filing Date

May 14, 2001

Group Art Unit

1645 1647

(37 CFR §1.98(b))

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
FH	ARR	Wooley, et al. <i>Influence of a Recombinant Human Soluble Tumor Necrosis Factor Receptor FC Fusion Protein on Type II Collagen-Induced Arthritis in Mice.</i> Journal of Immunology 151(11):6442-6607 (1993).
FH	ASS	Vey, et al. <i>IFN-γ and 1,25(OH)$_2$D$_3$ Induce on THP-1 Cells Distinct Patterns of Cell Surface Antigen Expression, Cytokine Production, and Responsiveness to Contact with Activated T Cells.</i> Journal of Immunology 149(6):2040-2046 (1992).
FH	ATT	Courtenay, et al. <i>Immunisation against heterologous type II collagen induces arthritis in mice.</i> Nature 283(5748): 666-668 (1980).
FH	AUU	Burger, et al. <i>Imbalance between interstitial collagenase and tissue inhibitor of metalloproteinases 1 in synoviocytes and fibroblasts upon direct contact with stimulated T Lymphocytes.</i> Arthritis & Rheumatism 41(10):1748-1759 (1998).
FH	AVV	Kim, et al. <i>Targeting the IL-15 Receptor with an Antagonist IL-15 Mutant/Fcγ2a Protein Blocks Delayed-Type Hypersensitivity.</i> Journal of Immunology 160:5742-5748 (1998).
FH	AWW	Li, et al. <i>Induction of Allograft Tolerance in the Absence of Fas-Mediated Apoptosis.</i> Journal of Immunology 163:2500-2507 (1999).
FH	AXX	Kim, et al. <i>Targeting the IL-15 Receptor with an Antagonist IL-15/Fcγ2a Protein Blocks DTH and Enhances the Acceptance of Islet Allografts.</i> 17 th ASTP (Physicist) Annual Meeting, Chicago, IL May 9-13, 1998 (p. 713).
FH	AYY	Kirk, et al. <i>Treatment of humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates.</i> Nature Medicine 5(6):686-693 (1999).
FH	AZZ	Nickerson, et al. <i>Prolonged islet allograft acceptance in the absence of interleukin 4 expression.</i> Transplant Immunology 4:81-85 (1996).
FH	AAAA	Lakkis, et al. <i>Interleukin 4 receptor targeted cytotoxicity: genetic construction and in vivo immunosuppressive activity of a diphtheria toxin-related murine interleukin 4 fusion protein.</i> Eur. J. Immunol. 21:2253-2258 (1991).
FH	ABBB	Li, et al. <i>Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance.</i> Nature Medicine 5(11):1298-1302 (1999).

Examiner Signature

Terry B. Strom

Date Considered

12/01/03

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)